EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial

Perioperatives Toripalimab plus neoadjuvante Chemotherapie könnte die Ergebnisse bei resektablem Ösophaguskarzinom verbessern: Interimsanalyse einer randomisierten Phase-III-Studie

Yan Zheng iD, Guanghui Liang, Dongfeng Yuan, Xianben Liu, Yufeng Ba, Zimin Qin, Sining Shen, Zhenxuan Li, Haibo Sun, Baoxing Liu, Quanli Gao, Peng Li und 19 weitere

Cancer Communications · 2024-10 · 44 (10) · 1214-1227

DOI: 10.1002/cac2.12604 ↗

Auf einen Blick

In dieser Interimsanalyse bei resektablem ESCC war Toripalimab plus neoadjuvante Chemotherapie mit höheren 1-Jahres-EFS- und OS-Raten verbunden als Chemotherapie allein.

Fragestellung

Vergleicht perioperatives Toripalimab plus neoadjuvante Chemotherapie mit neoadjuvanter Chemotherapie allein bei resektablem ESCC Sicherheit und Wirksamkeit?

Methode

Prospektive, monozentrische, offene, randomisierte Phase-III-Studie am Henan Cancer Hospital; 2 Zyklen alle 3 Wochen, danach Operation; Interimsanalyse.

Ergebnisse

252 Patient:innen; 127 Toripalimab, 125 Chemotherapie. 1-Jahres-EFS 77,9 % vs. 64,3 %; HR 0,62 (95 %-KI 0,39–1,00). 1-Jahres-OS 94,1 % vs. 83,0 %; HR 0,48 (95 %-KI 0,24–0,97). pCR 18,6 % vs. 4,6 %.

Einschränkungen

Interimsanalyse einer laufenden Studie; die Langzeitergebnisse sind noch nicht vollständig.

Schlussfolgerung der Autor:innen

Die Interimsresultate zeigten, dass die Zugabe von perioperativem Toripalimab zu NAC bei resektablem ESCC sicher ist, das OS verbessern könnte und die Standardtherapie künftig verändern könnte.

Kernaussagen

  • 1-Jahres-EFS: 77,9 % vs. 64,3 %; HR 0,62 (95 %-KI 0,39–1,00)
  • 1-Jahres-OS: 94,1 % vs. 83,0 %; HR 0,48 (95 %-KI 0,24–0,97)
  • pCR höher mit Toripalimab: 18,6 % vs. 4,6 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Communications, online erschienen am 02.09.2024. Verfasst von Yan Zheng und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Neoadjuvant Therapy, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Central Plains Young Top Talent, Henan Province Medical Science and Technology Key Projects Coconstructed by the Ministry of Health, Wu Jieping Medical Foundation.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the era of immunotherapy, neoadjuvant immunochemotherapy (NAIC) for the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) is used clinically but lacks of high‐level clinical evidence. This study aimed to compare the safety and long‐term efficacy of NAIC followed by minimally invasive esophagectomy (MIE) with those of neoadjuvant chemotherapy (NAC) followed by MIE.

Methods

A prospective, single‐center, open‐label, randomized phase III clinical trial was conducted at Henan Cancer Hospital, Zhengzhou, China. Patients were randomly assigned to receive either neoadjuvant toripalimab (240 mg) plus paclitaxel (175 mg/m 2 ) + cisplatin (75 mg/m 2 ) (toripalimab group) or paclitaxel + cisplatin alone (chemotherapy group) every 3 weeks for 2 cycles. After surgery, the toripalimab group received toripalimab (240 mg every 3 weeks for up to 6 months). The primary endpoint was event‐free survival (EFS). The pathological complete response (pCR) and overall survival (OS) were key secondary endpoints. Adverse events (AEs) and quality of life were also assessed.

Results

Between May 15, 2020 and August 13, 2021, 252 ESCC patients ranging from T1N1‐3M0 to T2‐3N0‐3M0 were enrolled for interim analysis, with 127 in the toripalimab group and 125 in the chemotherapy group. The 1‐year EFS rate was 77.9% in the toripalimab group compared to 64.3% in the chemotherapy group (hazard ratio [HR] = 0.62; 95% confidence interval [CI] = 0.39 to 1.00; P = 0.05). The 1‐year OS rates were 94.1% and 83.0% in the toripalimab and chemotherapy groups, respectively (HR = 0.48; 95% CI = 0.24 to 0.97; P = 0.037). The patients in the toripalimab group had a higher pCR rate (18.6% vs. 4.6%; P = 0.001). The rates of postoperative Clavien‐Dindo grade IIIb or higher morbidity were 9.8% in the toripalimab group and 6.8% in the chemotherapy group, with no significant difference observed ( P = 0.460). The rates of grade 3 or 4 treatment‐related AEs did not differ between the two groups (12.5% versus 12.4%).

Conclusions

The interim results of this ongoing trial showed that in resectable ESCC, the addition of perioperative toripalimab to NAC is safe, may improve OS and might change the standard treatment in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsNeoadjuvant TherapyAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedProspective StudiesEsophageal Squamous Cell CarcinomaEsophagectomyPaclitaxelCisplatinAdultTreatment Outcome

Stichwörter der Autor:innen

esophageal squamous cell carcinomaminimally invasive esophagectomyneoadjuvant chemotherapyneoadjuvant immunochemotherapysurvival

Substanzen

Antibodies, Monoclonal, HumanizedtoripalimabPaclitaxelCisplatin

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
  • Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
  • Department of Endoscopy, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
  • Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
  • Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
  • Department of Biobank, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.

ORCID-Profile: Yan Zheng, Jie Ma, Wenqun Xing

Förderung

  • Central Plains Young Top Talent
  • Henan Province Medical Science and Technology Key Projects Coconstructed by the Ministry of Health
  • Wu Jieping Medical Foundation
  • Henan Province Health Science and Technology Innovation Outstanding Young Talent Training Project
  • National Natural Science Foundation of China

Zitieren

APA

Zheng, Y., Liang, G., Yuan, D., Liu, X., Ba, Y., Qin, Z., Shen, S., Li, Z., Sun, H., Liu, B., Gao, Q., Li, P., Wang, Z., Liu, S., Zhu, J., Wang, H., Ma, H., Liu, Z., Zhao, F., …, & Xing, W. (2024). Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial. Cancer Communications, 44(10), 1214-1227. https://doi.org/10.1002/cac2.12604

Vancouver

Zheng Y, Liang G, Yuan D, Liu X, Ba Y, Qin Z, et al. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial. Cancer Communications. 2024;44(10):1214-1227. doi:10.1002/cac2.12604

BibTeX
@article{Zheng2024,
  author = {Zheng, Yan and Liang, Guanghui and Yuan, Dongfeng and Liu, Xianben and Ba, Yufeng and Qin, Zimin and Shen, Sining and Li, Zhenxuan and Sun, Haibo and Liu, Baoxing and Gao, Quanli and Li, Peng and Wang, Zongfei and Liu, Shilei and Zhu, Jianping and Wang, Haoran and Ma, Haibo and Liu, Zhenzhen and Zhao, Fei and Zhang, Jun and Zhang, He and Wu, Daoyuan and Qu, Jinrong and Ma, Jie and Zhang, Peng and Ma, Wenjie and Yan, Ming and Yu, Yongkui and Li, Qing and Zhang, Jiangong and Xing, Wenqun},
  title = {Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial},
  journal = {Cancer Communications},
  year = {2024},
  volume = {44},
  number = {10},
  pages = {1214--1227},
  doi = {10.1002/cac2.12604}
}
Kostenlos starten →